班达穆斯丁与凝胺和维诺雷尔结合使用,作为对复发性或耐火性外围T细胞淋巴瘤的救援方案:回顾单中心经验
Filippo Bagnoli1,2, Jacopo Calabrese De Feo1,2, Francesca Ricci1
1Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
British journal of haematology
|January 22, 2026
概括
BeGeV组合疗法对复发/耐药的外围T细胞淋巴瘤 (PTCL) 显示出前景,改善了反应率,并为特定亚型提供了潜在的干细胞移植桥梁.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 周围T细胞淋巴瘤 (PTCL) 的预后不好,特别是在复发/耐药 (r/r) 病例中,其二线治疗选择有限.
- 全基性造血干细胞移植 (alloHSCT) 对于持久缓解至关重要,需要改进救援疗法以提高移植资格.
研究的目的:
- 追溯评估在患有r/r PTCL的患者中达穆斯丁,格姆西塔宾和维诺雷尔宾 (BeGeV) 组合的疗效.
- 评估BeGeV方案的潜力,作为一个桥梁 alloHSCT.
主要方法:
- 自2017年以来,对24名连续接受BeGeV治疗的r/r PTCL患者进行了回顾性分析.
- 评估整体反应率 (ORR),完全缓解率 (CRR),无进展生存率 (PFS) 和整体生存率 (OS).
主要成果:
- 在r/r PTCL中,BeGeV实现了66%的ORR和41%的CRR.
- 一年的PFS和OS分别为37.5%和58.3%.
- 在PTCL亚型中观察到响应和生存的显著差异,T卵泡辅助体 (PTCL-TFH) 和全身形大细胞淋巴瘤 (sALCL) 显示出比PTCL没有另有说明 (PTCL-NOS) 更好的结果.
结论:
- BeGeV在r/r PTCL中显示了初步的疗效,在PTCL-TFH和sALCL亚型中具有显著的活性.
- BeGeV疗法可以作为一种有价值的桥梁,为特定PTCL亚型的符合条件的患者分配HSCT.
- 进一步的前性研究是有必要的,以证实这些发现,由于研究的回顾性质和小样本大小.
相关概念视频
Drug Dosage Regimen: Overview
4.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.4K
Dosage Regimen: Individualization
171
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
171
Dosage Regimens: Partial Pharmacokinetic Parameters
157
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
157
Dosage Regimen: Multiple Oral Dosage
234
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
234
Insulin: Dosing Regimen and Adverse Effects
705
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
705
Dosage Regimens: Designs and Approaches
270
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
270


